3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
15
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Keratosis, Actinic
1
Interventions
pembrolizumab
70
Nivolumab
47
Ipilimumab
27
Specimen Handling
15
Magnetic Resonance Spectroscopy
15
trametinib
14
Biopsy
13
dabrafenib
11
cemiplimab
11
avelumab
11
Cyclophosphamide
11
binimetinib
10
Radiotherapy
9
CTLA-4 Antigen
9
fludarabine
8
encorafenib
7
atezolizumab
7
Radiosurgery
7
Immunoglobulin G
7
Disulfides
7
Cisplatin
7
fludarabine phosphate
6
durvalumab
6
tislelizumab
5
relatlimab
5
lenvatinib
5
dostarlimab
5
Pemetrexed
5
Paclitaxel
5
Introns
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Diclofenac
×
Dermatologic
×
Clear all
NCT05387525
2025-02-11
AKtive
Almirall, S.A.
Phase 4
Active not recruiting
447 enrolled